Symbols

DMAC

Diamedica·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DMAC

Diamedica Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing novel recombinant protein therapeutics for the treatment of acute ischemic stroke and chronic kidney disease

Industry

Biological Technology

Established Date

01/21/2000

Listing Date

12/07/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.diamedica.com

Security Type

Common stock

Office address

301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305

Business

Introduction

Diamedica Therapeutics Inc., was originally incorporated under the Companies Act (Manitoba) through its articles of association on January 21, 2000. On May 31, 2019, the company continued to exist from the company formed under the CBCA to the province of British Columbia formed under the BCBCA. The company is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with serious diseases. DM199, the lead drug candidate for Diamedica therapy, is the first recombinant (synthetic) form of human tissue kallikrein 1 (KLK1) protein with drug activity to be studied in patients.

Earnings Call

Q1/2025

Estimate EPS-0.18

Actual EPS-0.18

Estimate Revenue--

Actual Revenue0

Contradictions Uncovered: Analyzing DM199's Clinical Trial Progress and Key Challenges

May 20,2025 07:44·
Earnings Decrypt

Q2/2025

Estimate EPS-0.19

Actual EPS-0.18

Estimate Revenue--

Actual Revenue0

DiaMedica's Q2 2025: Unpacking Contradictions in Stroke Study Timelines and Preeclampsia Prospects

Aug 13,2025 11:44·
Earnings Decrypt

Company Financials

EPS

DMAC has released its 2025 Q3 earnings. EPS was reported at -0.17, versus the expected -0.16, missing expectations. The chart below visualizes how DMAC has performed over recent quarters, highlighting trends in earnings surprises.